Andere Sprachen Pharvaris N.V.

Aktien

A2QNWS

NL00150005Y4

PHVS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
23.35 ^USD	+2.55%		+21.87%	-16.76%

15.04.	PHARVARIS N.V. : Morgan Stanley bleibt bei seiner Kaufempfehlung	ZM
10.04.	Pharvaris verringert Q4-Nettoverlust; stellt neuen CFO ein	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pharvaris Files Mixed Shelf	12.04.
Pharvaris Narrows Q4 Net Loss; Hires New CFO	10.04.
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	10.04.
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	10.04.
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10.04.
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10.04.
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference	04.04.
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18.03.
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18.03.
Pharvaris N : Poster	15.03.
Pharvaris N : EGM Meeting Minutes	12.03.
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K	06.03.
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06.03.
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06.03.
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05.03.
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05.03.
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22.02.
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22.02.
Pharvaris Announces Extraordinary Meeting of Shareholders	16.02.
Pharvaris Announces Extraordinary Meeting of Shareholders	16.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pharvaris N.V.

Aktien

A2QNWS

NL00150005Y4

PHVS

Andere Sprachen

Filter